| Name | Title | Contact Details |
|---|
We are harnessing the power of the immune system to target some of the most challenging solid tumor malignancies.
Minute Molecular Diagnostics was founded in 2017 as a spinout of the Northwestern University Center for Innovation in Global Health Technology (CIGHT). Comprised of a strong management team with extensive diagnostic industry experience, the company has raised $8 million in funding from the NIH and Diagnostic Industry Executives.
BioStar Ventures continues to build a solid track record as an early-stage, value-added venture investor in disruptive cardiovascular and orthopaedic medical technologies by combining the insight of seasoned venture capitalists with the expertise of world-renowned medical thought leaders in clinical practice to attract unique deal flow, mitigate investment risk, optimize product development, and secure successful exit.
Artel is the global technology leader in ultra low volume liquid delivery measurement and quality assurance. The company develops and manufactures the most accurate, precise and easy-to-use systems available for ensuring liquid delivery data integrity and NIST-traceable results in life sciences laboratories. Artel innovations help laboratories improve processes and increase productivity, enhance product quality, and address compliance challenges.
Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) is a team of approximately 200 committed people working with passion to identify meaningful new medicines to advance the care of people with kidney disease. We have assembled a deep concentration of kidney care experts, including nephrologists, renal dietitians, nurses and industry veterans in nephrology. Together, we strive to raise awareness of the kidney disease epidemic, give voice to this underserved population, and help healthcare professionals to improve the care of their patients. In September 2014, the U.S. Food and Drug Administration approved Keryx`s first medicine, Auryxia® (ferric citrate) tablets. Keryx established its corporate headquarters in Boston`s innovation district to support the U.S. launch of Auryxia. Patients have been and continue to be at the center of our nearly 20 year corporate history.